Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design - Tevaarwerk, Amye; Wilding, George; Eickhoff, Jens; Chappell, Rick; Sidor, Carolyn; Arnott, Jamie; Bailey, Howard; Schelman, William; Liu, Glenn (Investigational new drugs, 2012)
Keywords: Adult; Aged; Algorithms; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Binding sites; Cancer; Cancer therapies; Cell cycle; Clinical trials; Diarrhea; Dose-Response Relationship, Drug; Drug dosages; Drug therapy; Enrollments; Female; Humans; Indoles - administration & dosage; Indoles - adverse effects; Indoles - pharmacokinetics; Male; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Oncology; Patients; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Phase I Studies; Radiation therapy; Studies; Toxicity; Tumors; Vomiting; United States--US; MKC-1; TITE-CRM; Novel dose escalation designs; Solid malignancy